Clinical Trials

Deciphera starts new study of rebastinib in solid tumors

Deciphera Pharmaceuticals has initiated an open-label, multicenter, phase 1b/2 study of rebastinib, the company’s investigational small molecule switch control inhibitor of TIE2 kinase, in combination with carboplatin in patients with advanced or metastatic solid tumors.

Spectrum Pharmaceuticals announces full enrollment of poziotinib EGFR cohort for previously treated NSCLC

Spectrum Pharmaceuticals has announced full enrollment of cohort 1 (N=87) for previously treated non-small cell lung cancer (NSCLC) patients with EGFR exon 20 insertion mutations with sites across the US, Europe, and Canada.

Astellas, Pfizer’s XTANDI meets primary endpoint in phase 3 prostate cancer trial

Astellas Pharma and Pfizer reported that the phase 3 ARCHES trial evaluating XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC) met its primary endpoint, improving radiographic progression-free survival (rPFS) significantly in comparison to ADT alone.

AstraZeneca’s Lynparza succeeds in SOLO-3 ovarian cancer trial

Lynparza (olaparib), a poly ADP-ribose polymerase (PARP) inhibitor, co-developed by AstraZeneca and Merck (known as MSD outside the US and Canada), has succeeded in a phase 3 trial held in patients with relapsed BRCA-mutated (BRCAm) advanced ovarian cancer by meeting the primary endpoint.

Teva reports positive results for fremanezumab in phase IIIb migraine trial

Teva Pharmaceutical Industries said that the phase IIIb FOCUS study that evaluated the efficacy and safety of fremanezumab for the preventive treatment of migraine in adult patients has yielded positive results.

Vedanta begins phase 2 trial of LBP candidate VE303 for rCDI

Vedanta Biosciences, which was founded by PureTech Health, has commenced a phase 2 study of its rationally-defined bacterial consortium product candidate, VE303, for recurrent Clostridium difficile infection (rCDI).

Janssen’s Tremfya meets primary endpoint in phase 3 psoriasis trial

Janssen Pharmaceutical said that Tremfya (guselkumab) was found to be superior to Cosentyx (secukinumab) for the primary endpoint assessed at week 48 of a phase 3 trial in adults with moderate to severe plaque psoriasis.

Ra Pharma’s zilucoplan meets primary endpoints in phase 2 gMG trial

Ra Pharmaceuticals’ (Ra Pharma) zilucoplan has succeeded in a phase 2 trial in generalized myasthenia gravis (gMG) by meeting the primary and key secondary end points.

BMS, Vedanta Biosciences to evaluate Opdivo-VE800 combo in metastatic cancers

Bristol-Myers Squibb will evaluate Opdivo (nivolumab) in combination with Vedanta Biosciences’ VE800, a live biotherapeutic product (LBP), in patients with advanced or metastatic cancers.